NUVL Company Profile and Key Details

NUVL has shown sold momentum, gaining 6.83% over the past week and 14.49% over the past quarter, though year-to-date performance is up 5.31%. Short-term trend indicators are mixed aligned (SMA20 0.76%, SMA50 0.41%, SMA200 16.26%). The stock’s 14-day RSI is 51.07 (neutral), while the ATR of 4.47 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -8.04% below its high and over 87.14% above its low. Average 10-day trading volume of 492.02 thousand shares is in line with the 3-month average of 518.50 thousand, indicating normal recent market interest.

Nuvalent, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.19. This means the shares are trading above this model’s fair value.

Nuvalent, Inc. has 66.67 million shares outstanding. The public float is 41.56 million shares, elevated short interest at 17.88% of float. This equals 5.54 million shares. The short ratio is 11.1 days. Institutional investors hold 112.31% of the float. Insiders own 2.84%. Flynn James E holds 8.30 million shares, Hack Andrew A. F. has 1.45 million shares and Porter James Richard has 278.63 thousand shares. Over the past six months, insider transactions show net selling. They sold 506.88 thousand shares across 44 transactions.

Nuvalent, Inc. generated EPS of -$5.32 over the past year. Five-year average earnings growth is -74.22%. Wall Street analysts project EPS growth of -2.52% annually over the next five years. The latest quarter delivered EPS of -$1.70. The next quarter is forecast at -$1.48. Next year's EPS is expected at -$33.16. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $158.00 to $100.00. The high target offers 52.03% upside. The low target suggests -3.78% downside. The mean target is $129.04. This offers 24.16% upside. Nuvalent, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 22.3%. The prior quarter beat by 3.15%. Over the last six quarters, Apple has recorded several small beats. These include 16.43% in August 08, 2024.

Nuvalent, Inc. (NASDAQ:NUVL) closed at $103.93 USD, losing -$0.60 (-0.57%) from the previous close of $104.53. The stock is currently mid-range between its 52-week high and low $55.53 and $113.02. With a market capitalization of about $7.56 billion, Nuvalent, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 528.18 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Nuvalent, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James R. Porter, the company employs approximately 162 people and listed since July 29, 2021. Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.

Nuvalent, Inc. (NASDAQ:NUVL) shares are flat 5.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nuvalent, Inc. trading at a premium to the broader market with a P/E of -19.48. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $109.66, suggesting 5.51% upside. Our AI forecast model points to short-term weakness (-1.41% over two weeks), a medium-term rise (22.01% over three months), and a longer-term gain (22.78% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Nuvalent, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.41%, with price expected at $102.46 by March 12, 2026, within a range of $99.33 to $105.44 3-Month Outlook: Projected rise of 22.01%, reaching $126.81 by May 27, 2026, with a range of $121.98 to $131.83. 1-Year Outlook: Projected gain of 22.78%, with price at $127.61 by February 26, 2027, within a range of $122.99 to $131.79.

Nuvalent, Inc. trades at a P/E ratio of -19.48, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.79 trading at moderately above to book value. The P/FCF stands at -28.38, also below market averages.